Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InsmedINSM +0.27%70 10-Year ROIIC % is -169.69 as of Dec. 2025. GuruFocus rates INSM with a GF Score™ of 70/100 and a GF Value™ of $187.82 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,104 Biotechnology companies, Insmed ranks worse than 76% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Insmed's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was -169.69%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Insmed's 10-Year ROIIC % or its related term are showing as below:
INSM's 10-Year ROIIC % is ranked worse than 76% of 1104
companies
in the Biotechnology industry
Industry Median: -19.8
vs INSM: -169.69
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Insmed 10-Year ROIIC % Related Terms
Insmed 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Insmed's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INSM vs INCY, BNTX, MRNA: 10-Year ROIIC % Comparison
For the Biotechnology subindustry, Insmed's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed 10-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Insmed's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Insmed (INSM) has a 10-Year ROIIC % of -169.69 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Insmed and its competitors. According to the industry distribution chart, Insmed ranks #839 out of 1104 companies in the Biotechnology industry, placing it in the top 76%.
Is Insmed's 10-Year ROIIC % too high?
Insmed's current 10-Year ROIIC % is -169.69. Based on the distribution chart, Insmed ranks #839 out of 1104 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Insmed has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's 10-Year ROIIC % compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #839 out of 1104 companies for 10-Year ROIIC %. This places Insmed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Biotechnology company?
A good 10-Year ROIIC % depends on the Biotechnology industry context. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Insmed and its competitors. Insmed's current 10-Year ROIIC % is -169.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (INSM) is currently considered Possible Value Trap. The stock's GF Value™ is $187.82, compared to a current price of $99.02 — trading 47.3% below its estimated fair value. The current 10-Year ROIIC % is -169.69. Insmed's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Insmed (INSM), the current 10-Year ROIIC % is -169.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of $99.02 is trading 47.3% below its estimated GF Value™ of $187.82.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for INSM:
10-Year ROIIC %: -169.69
GF Value™: $187.82 vs. price of $99.02 (47.3% below fair value)
No single metric tells the full story. See the INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
70GF Score
Get the complete analysis for INSM
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INSM has been successfully added to your 
